Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation “can eliminate detectable disease.”
Overall, 20% of the patients treated reached the primary endpoint — undetectable prostate-specific antigen (PSA) and noncastrate levels of testosterone at 20 months, which the authors described as “no evidence of disease” (NED).
This endpoint “could not have been achieved with any single therapy alone,” they note.
“Although longer follow-up is needed to assess durability, this binary end point represents a first step toward establishing a paradigm of cure in patients with low-volume metastatic disease,” they conclude.
Read the abstract in Urology